Home Cart Sign in  
Chemical Structure| 189197-69-1 Chemical Structure| 189197-69-1

Structure of Ro 48-8071 fumarate
CAS No.: 189197-69-1

Chemical Structure| 189197-69-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ro 48-8071 Fumarate is an inhibitor of Oxidosqualene cyclase (OSC) with IC50 of 6.5 nM, also inhibits Ebola virus (EBOV) cell entry with IC50 of 1.74 μM and blocks cholesterol synthesis in HepG2 cells.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ro 48-8071 fumarate

CAS No. :189197-69-1
Formula : C27H31BrFNO6
M.W : 564.44
SMILES Code : O=C(C1=CC=C(OCCCCCCN(CC=C)C)C=C1F)C2=CC=C(Br)C=C2.O=C(O)/C=C/C(O)=O
MDL No. :MFCD05865242
InChI Key :XCYAYLWZCRGKDS-WLHGVMLRSA-N
Pubchem ID :9959583

Safety of Ro 48-8071 fumarate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ro 48-8071 fumarate

epigenetics
DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human umbilical vein endothelial cells (HUVECs) 1 µM 18-24 hours To evaluate the effect of Ro 48-8071 on endothelial cell migration and adhesion. Results showed that Ro 48-8071 significantly inhibited both VEGF-induced and baseline EC migration (by 52% and 57%, respectively) and significantly inhibited EC adhesion to different extracellular matrices (e.g., vitronectin, fibronectin, and collagen I) (by 61%, 58%, and 52%, respectively). Additionally, Ro 48-8071 significantly suppressed tube formation in the Matrigel assay (by 70%). Sci Rep. 2015 Mar 12;5:9054
Normal AG11132A mammary cells up to 10 µM 24 hours To determine the effect of RO 48-8071 on the viability of normal mammary cells, concentrations up to 10 μM had no effect on normal cells. Breast Cancer Res Treat. 2014 Jul;146(1):51-62
Neonatal mouse oligodendrocyte precursor cells 10 nM 24 hours Ro 48-8071 blocked TF-induced oligodendrocyte differentiation and inhibited TF-induced zymosterol accumulation Neurol Neuroimmunol Neuroinflamm. 2021 Oct 12;8(6):e1091.
HepG2 cells 0.113 µM (EC50) 24 hours To evaluate the effects of Ro 48-8071 on PXR-responsive reporter expression. Results showed that Ro 48-8071 significantly activated PXR-responsive reporter expression. Drug Metab Dispos. 2009 Apr;37(4):900-8.
Primary cultured human hepatocytes 3, 10, 30 µM 24 hours To evaluate the effects of Ro 48-8071 on CYP3A4 and CYP2B6 mRNA content. Results showed that Ro 48-8071 treatment significantly increased CYP3A4 and CYP2B6 mRNA levels. Drug Metab Dispos. 2009 Apr;37(4):900-8.
ZR-75 cells 11.04 ± 0.29 µM (24 h), 7.63 ± 0.30 µM (48 h) 24 hours and 48 hours To determine the effect of RO 48-8071 on the viability of ZR-75 cells, the IC50 values were found to be 11.04 ± 0.29 μM at 24 h and 7.63 ± 0.30 μM at 48 h. Breast Cancer Res Treat. 2014 Jul;146(1):51-62
HCC-1428 cells 14.64 ± 0.42 µM (24 h), 11.58 ± 0.34 µM (48 h) 24 hours and 48 hours To determine the effect of RO 48-8071 on the viability of HCC-1428 cells, the IC50 values were found to be 14.64 ± 0.42 μM at 24 h and 11.58 ± 0.34 μM at 48 h. Breast Cancer Res Treat. 2014 Jul;146(1):51-62
MCF-7 cells 12.32 ± 0.59 µM (24 h), 6.34 ± 0.34 µM (48 h) 24 hours and 48 hours To determine the effect of RO 48-8071 on the viability of MCF-7 cells, the IC50 values were found to be 12.32 ± 0.59 μM at 24 h and 6.34 ± 0.34 μM at 48 h. Breast Cancer Res Treat. 2014 Jul;146(1):51-62
T47-D cells 11.53 ± 0.36 µM (24 h), 7.76 ± 0.29 µM (48 h) 24 hours and 48 hours To determine the effect of RO 48-8071 on the viability of T47-D cells, the IC50 values were found to be 11.53 ± 0.36 μM at 24 h and 7.76 ± 0.29 μM at 48 h. Breast Cancer Res Treat. 2014 Jul;146(1):51-62
BT-474 cells 9.51 ± 0.05 µM (24 h), 6.06 ± 0.23 µM (48 h) 24 hours and 48 hours To determine the effect of RO 48-8071 on the viability of BT-474 cells, the IC50 values were found to be 9.51 ± 0.05 μM at 24 h and 6.06 ± 0.23 μM at 48 h. Breast Cancer Res Treat. 2014 Jul;146(1):51-62
PANC-1 cells 1, 3, 10, 30, 100 µM 24, 48, 72 hours RO inhibited PANC-1 cell viability in a dose- and time-dependent manner. The inhibitory ratio was approximately 40% at 10 µM after 72 h and 80% at 30 and 100 µM. Mol Med Rep. 2021 Dec;24(6):828
KLE cells 6.478 µM (IC50) 48 hours Ro 48-8071 significantly inhibited EC cell proliferation Cell Death Discov. 2025 Feb 8;11(1):55
Ishikawa cells 0.968 µM (IC50) 48 hours Ro 48-8071 significantly inhibited EC cell proliferation Cell Death Discov. 2025 Feb 8;11(1):55
Plasmodium falciparum 3D7 clone 4.5 ± 0.3 µM (IC50) 48 hours Ro 48-8071 significantly inhibited MQ-4 biosynthesis, reducing it by 88.2 ± 11%, while UQ increased by 30 ± 5%. FEBS Lett. 2010 Dec 1;584(23):4761-4768
Helix lucorum neurons 2 µM 60 minutes Ro 48-8071 2 μM decreased the average rate of ACh-induced current depression and did not change the level of spontaneous recovery. The ACh-current amplitude declined constantly in time and did not reach the steady-state level. Cell Mol Neurobiol. 2017 Nov;37(8):1443-1455
Pancreatic ductal adenocarcinoma cells (HPAF-II) 1 µM 9 hours To evaluate the effect of Ro 48-8071 on Akt and ERK phosphorylation in HPAF-II cells. Results showed that Ro 48-8071 significantly inhibited Akt and ERK phosphorylation. Sci Rep. 2015 Mar 12;5:9054
Colon cancer cells (HCT116) 1 µM 9 hours To evaluate the effect of Ro 48-8071 on Akt and ERK phosphorylation in HCT116 cells. Results showed that Ro 48-8071 significantly inhibited Akt and ERK phosphorylation. Sci Rep. 2015 Mar 12;5:9054

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice RIP-Tag2 transgenic mouse model (spontaneous neuroendocrine pancreatic tumor model), HCT116 human colon carcinoma xenograft model, HPAF-II human pancreatic ductal adenocarcinoma xenograft model Oral 10 mg/kg/dayaily Once daily for 4 weeks (RIP-Tag2 model) or 2 weeks (HCT116 and HPAF-II models) To evaluate the effect of Ro 48-8071 on tumor growth, angiogenesis, and metastasis. Results showed that Ro 48-8071 significantly inhibited tumor growth in RIP-Tag2 mice (by 40%) and significantly reduced tumor volume in HCT116 and HPAF-II xenograft models (by 46% and 47%, respectively). Additionally, Ro 48-8071 significantly reduced lung metastasis in the HCT116 model (number and incidence reduced by 81% and 53%, respectively) and liver metastasis in the HPAF-II model (incidence and number reduced by 75% and 60%, respectively). Ro 48-8071 also significantly reduced tumor vessel area (by 49%, 67%, and 56% in RIP-Tag2, HCT116, and HPAF-II, respectively) and increased pericyte coverage (by 44%, 33%, and 31% in RIP-Tag2, HCT116, and HPAF-II, respectively). Furthermore, when combined with 5-fluorouracil (5-FU), Ro 48-8071 significantly enhanced anti-tumor and anti-metastatic effects (tumor growth inhibition by 71%, lung metastasis incidence and number reduced by 83% and 89%, respectively). Sci Rep. 2015 Mar 12;5:9054
BALB/c mice BALB/c mice Oral 20 mg/day/kg Daily, for 7 to 21 days Ro 48-8071 led to a rapid and sustained inhibition (>50%) of cholesterol synthesis in the small intestine. Hepatic cholesterol synthesis was markedly suppressed initially but rebounded to higher than baseline rates within 7 days. Whole body cholesterol synthesis, fractional cholesterol absorption, and fecal neutral and acidic sterol excretion were not consistently changed. Biochem Pharmacol. 2014 Apr 1;88(3):351-63
Nude mice Subcutaneous tumor model Oral 20 mg/kg Once daily, during the experiment Ro 48-8071 significantly inhibited xenograft tumor growth Cell Death Discov. 2025 Feb 8;11(1):55
C57L/J mice Cholesterol cholelithiasis model Oral 30-100 mg/kg/day Once daily for 56 days To assess the potential of Ro 48-8071 in preventing cholesterol cholelithiasis in C57L/J mice. Results showed that Ro 48-8071 significantly reduced gallstone prevalence and increased biliary phospholipid secretion rates. Gut. 2004 Jan;53(1):136-42
BALB/c nude mice Subcutaneous tumor xenograft model Intravenous injection 5 mg/kg/day Once daily for the first 5 days, then once every other day for six more injections RO significantly inhibited subcutaneous tumor growth in nude mice, with marked reductions in tumor volume and weight. Mol Med Rep. 2021 Dec;24(6):828
Nude mice BT-474 tumor xenografts Intravenous injection 5 or 10 mg/kg Daily for 5 days, followed by an injection every other day for five additional treatments and then a final injection 2 h prior to sacrifice To evaluate the effect of RO 48-8071 on BT-474 tumor xenografts, RO significantly suppressed tumor growth with no apparent toxicity. Breast Cancer Res Treat. 2014 Jul;146(1):51-62

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.86mL

1.77mL

0.89mL

17.72mL

3.54mL

1.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories